Montefiore Einstein is distinguished by having been awarded two designations  by the National Multiple Sclerosis Society, the preeminent professional society in the field: as a Multiple Sclerosis Centers of Comprehensive Care, and Partners in MS Care. These awards acknowledge our ability to greatly refine targeted treatment strategies through caring for the most diverse patient populations, and delivering individualized care within the patients’ local communities. We are also recipients of the“Together for a Cure” Greater New York City Hope Award, for our dedicated MS service to the Westchester community.

 As an example of our ongoing innovation, Montefiore Einstein was selected to participate in  REMODEL-1, a randomized multicenter phase 3 trial to evaluate the safety and efficacy of remibrutinib, compared to teriflunomide, an already FDA-approved oral MS treatment for patients with relapsing MS. The study compares the effects of treatment on relapse rates. Remibrutinib is an oral Bruton’s tyrosine kinase (BTK) enzyme inhibitor, which is expected to decrease the neuroinflammatory activity that damages nerve cells in the brain, spinal cord and optic nerves in patients with MS. The trial will support regulatory approval and access to a potential, and otherwise unavailable, new oral treatment for patients with relapsing MS, which could prevent new MS relapses and disability. 

 We were also selected to participate in the PoNS Therapeutic Experience Program (PoNSTEP), an open-label observational interventional multi-center trial designed to evaluate the impact of patient adherence to Portable Neuromodulation Stimulator (PoNS) therapy—a rehabilitation program which combines the use of the PoNS device with physical therapy—on functional outcomes, and improvement in gait deficits in patients with MS. The Portable Neuromodulation Stimulator is an oral device with a controller and mouthpiece that electrically stimulates the surface of the tongue to help improve balance and gait. This study is being conducted in conjunction with Montefiore Einstein’s renowned Burke Rehabilitation Hospital and Montefiore Nyack. 

We are among the highest-performing centers in the nation for neurology and neurosurgery. Montefiore Einstein’s Burke Rehabilitation Hospital is ranked in the top one percent of all U.S. hospitals for rehabilitation, according to U.S. News & World Report. Additionally, we are recipients of the highest standard for rehabilitation medicine, a three-year designation granted by the Commission on Accreditation of Rehabilitation Facilities (CARF).

If you are interested in participating or enrolling a patient in a clinical trial, please call 718-920-2000.